Novartis AG Cash Flow Conversion Efficiency
Novartis AG cash flow conversion efficiency. Based on the latest financial reports, Novartis AG (NOVN) has a cash flow conversion efficiency ratio of 0.092x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF3.60 Billion ≈ $4.55 Billion USD) by net assets (CHF39.04 Billion ≈ $49.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Novartis AG (1998–2025)
Cash flow conversion efficiency of Novartis AG from 1998 to 2025. This chart illustrates how Novartis AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NOVN stock price for real-time trading data and today's change.
Novartis AG Cash Flow Conversion Ratio Explained
Novartis AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Novartis AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novartis AG ranked by their cash flow conversion efficiency. Also see market cap of Novartis AG for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Siemens Aktiengesellschaft
XETRA:SIE
|
0.058x |
|
BHP Group
MX:BHPN
|
0.061x |
|
International Business Machines
NYSE:IBM
|
0.075x |
|
Nestlé S.A
F:NESM
|
0.137x |
|
Arm Holdings plc American Depositary Shares
NASDAQ:ARM
|
0.105x |
|
American Express Company
NYSE:AXP
|
0.112x |
|
Linde plc Ordinary Shares
NASDAQ:LIN
|
0.056x |
|
Citigroup Inc.
NYSE:C
|
-0.103x |
Annual Cash Flow Conversion Efficiency for Novartis AG (1998–2025)
The table below shows the annual cash flow conversion efficiency of Novartis AG from 1998 to 2025. Review NOVN free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF46.52 Billion ≈ $58.81 Billion |
CHF20.05 Billion ≈ $25.35 Billion |
0.431x | +7.97% |
| 2024-12-31 | CHF44.13 Billion ≈ $55.79 Billion |
CHF17.62 Billion ≈ $22.28 Billion |
0.399x | +29.11% |
| 2023-12-31 | CHF46.75 Billion ≈ $59.10 Billion |
CHF14.46 Billion ≈ $18.28 Billion |
0.309x | +29.09% |
| 2022-12-31 | CHF59.42 Billion ≈ $75.13 Billion |
CHF14.24 Billion ≈ $18.00 Billion |
0.240x | +7.81% |
| 2021-12-31 | CHF67.82 Billion ≈ $85.75 Billion |
CHF15.07 Billion ≈ $19.05 Billion |
0.222x | -7.75% |
| 2020-12-31 | CHF56.67 Billion ≈ $71.64 Billion |
CHF13.65 Billion ≈ $17.26 Billion |
0.241x | -1.79% |
| 2019-12-31 | CHF55.55 Billion ≈ $70.23 Billion |
CHF13.62 Billion ≈ $17.23 Billion |
0.245x | +35.24% |
| 2018-12-31 | CHF78.69 Billion ≈ $99.49 Billion |
CHF14.27 Billion ≈ $18.04 Billion |
0.181x | +6.67% |
| 2017-12-31 | CHF74.23 Billion ≈ $93.84 Billion |
CHF12.62 Billion ≈ $15.96 Billion |
0.170x | +10.97% |
| 2016-12-31 | CHF74.89 Billion ≈ $94.68 Billion |
CHF11.47 Billion ≈ $14.51 Billion |
0.153x | -0.67% |
| 2015-12-31 | CHF77.12 Billion ≈ $97.50 Billion |
CHF11.90 Billion ≈ $15.04 Billion |
0.154x | -21.36% |
| 2014-12-31 | CHF70.84 Billion ≈ $89.57 Billion |
CHF13.90 Billion ≈ $17.57 Billion |
0.196x | +10.89% |
| 2013-12-31 | CHF74.47 Billion ≈ $94.15 Billion |
CHF13.17 Billion ≈ $16.66 Billion |
0.177x | -13.68% |
| 2012-12-31 | CHF69.26 Billion ≈ $87.57 Billion |
CHF14.19 Billion ≈ $17.95 Billion |
0.205x | -5.56% |
| 2011-12-31 | CHF65.94 Billion ≈ $83.37 Billion |
CHF14.31 Billion ≈ $18.09 Billion |
0.217x | +7.63% |
| 2010-12-31 | CHF69.77 Billion ≈ $88.21 Billion |
CHF14.07 Billion ≈ $17.78 Billion |
0.202x | -4.97% |
| 2009-12-31 | CHF57.46 Billion ≈ $72.65 Billion |
CHF12.19 Billion ≈ $15.41 Billion |
0.212x | +9.54% |
| 2008-12-31 | CHF50.44 Billion ≈ $63.77 Billion |
CHF9.77 Billion ≈ $12.35 Billion |
0.194x | +3.88% |
| 2007-12-31 | CHF49.40 Billion ≈ $62.45 Billion |
CHF9.21 Billion ≈ $11.64 Billion |
0.186x | -11.60% |
| 2006-12-31 | CHF41.29 Billion ≈ $52.21 Billion |
CHF8.71 Billion ≈ $11.01 Billion |
0.211x | -13.43% |
| 2005-12-31 | CHF33.16 Billion ≈ $41.93 Billion |
CHF8.08 Billion ≈ $10.22 Billion |
0.244x | +13.45% |
| 2004-12-31 | CHF31.32 Billion ≈ $39.59 Billion |
CHF6.72 Billion ≈ $8.50 Billion |
0.215x | -1.47% |
| 2003-12-31 | CHF30.52 Billion ≈ $38.58 Billion |
CHF6.65 Billion ≈ $8.41 Billion |
0.218x | +5.93% |
| 2002-12-31 | CHF28.34 Billion ≈ $35.82 Billion |
CHF5.83 Billion ≈ $7.37 Billion |
0.206x | +18.68% |
| 2001-12-31 | CHF25.56 Billion ≈ $32.31 Billion |
CHF4.43 Billion ≈ $5.60 Billion |
0.173x | -14.50% |
| 2000-12-31 | CHF22.89 Billion ≈ $28.94 Billion |
CHF4.64 Billion ≈ $5.87 Billion |
0.203x | +9.95% |
| 1999-12-31 | CHF23.51 Billion ≈ $29.72 Billion |
CHF4.33 Billion ≈ $5.48 Billion |
0.184x | -1.03% |
| 1998-12-31 | CHF22.96 Billion ≈ $29.02 Billion |
CHF4.28 Billion ≈ $5.41 Billion |
0.186x | -- |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more